Go Premium

Notifications

TipRanks

Notifications

Tag: BHVN

Total 243 Posts

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medpace Holdings (MEDP), Biohaven Ltd. (BHVN) and Intra-Cellular Therapies (ITCI)

October 22, 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medpace Holdings (MEDP – Research Report), Biohaven Ltd. (BHVN – Research Report) and Intra-Cellular Therapies (ITCI – Research Report).

Medpace Holdings (MEDP)

In a report released yesterday, David Windley from Jefferies maintained a Hold rating on Medpace Holdings, with a price target of $345.00. The company’s shares closed last Monday at $352.92.

According to TipRanks.com, Windley is a 5-star analyst with an average return of 11.4% and a 62.0% success rate. Windley covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Fortrea Holdings Inc., and Molina Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medpace Holdings with a $384.71 average price target, representing a 7.5% upside. In a report issued on October 14, Truist Financial also maintained a Hold rating on the stock with a $397.00 price target.

See today’s best-performing stocks on TipRanks >>

Biohaven Ltd. (BHVN)

In a report released today, Amy Li from Jefferies assigned a Buy rating to Biohaven Ltd., with a price target of $64.00. The company’s shares closed last Monday at $51.34.

Li has an average return of 4.2% when recommending Biohaven Ltd..

According to TipRanks.com, Li is ranked #8107 out of 9147 analysts.

Currently, the analyst consensus on Biohaven Ltd. is a Strong Buy with an average price target of $64.45, implying a 23.4% upside from current levels. In a report issued on October 7, Bernstein also maintained a Buy rating on the stock with a $66.00 price target.

Intra-Cellular Therapies (ITCI)

In a report released today, Andrew Tsai from Jefferies assigned a Buy rating to Intra-Cellular Therapies, with a price target of $105.00. The company’s shares closed last Monday at $76.91.

According to TipRanks.com, Tsai is a 4-star analyst with an average return of 5.0% and a 57.5% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Vigil Neuroscience Inc, and Relmada Therapeutics.

Intra-Cellular Therapies has an analyst consensus of Strong Buy, with a price target consensus of $97.08, implying a 24.6% upside from current levels. In a report issued on October 11, Morgan Stanley also maintained a Buy rating on the stock with a $95.00 price target.

Read More on MEDP:

Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), PROCEPT BioRobotics (PRCT) and Travere Therapeutics (TVTX)

October 9, 2024

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biohaven Ltd. (BHVN – Research Report), PROCEPT BioRobotics (PRCT – Research Report) and Travere Therapeutics (TVTX – Research Report) with bullish sentiments.

Biohaven Ltd. (BHVN)

In a report issued on October 7, Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Ltd.. The company’s shares closed last Wednesday at $51.27.

According to TipRanks.com, Goodman is a 4-star analyst with an average return of 6.5% and a 48.2% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Intra-Cellular Therapies, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Biohaven Ltd. is a Strong Buy with an average price target of $63.45, implying a 18.6% upside from current levels. In a report issued on September 25, Jefferies also initiated coverage with a Buy rating on the stock with a $64.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

PROCEPT BioRobotics (PRCT)

In a report issued on October 7, Mike Kratky from Leerink Partners reiterated a Buy rating on PROCEPT BioRobotics, with a price target of $78.00. The company’s shares closed last Wednesday at $74.14.

According to TipRanks.com, Kratky is a 4-star analyst with an average return of 17.0% and a 52.2% success rate. Kratky covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Edwards Lifesciences, and Tandem Diabetes Care.

PROCEPT BioRobotics has an analyst consensus of Strong Buy, with a price target consensus of $80.25, an 8.4% upside from current levels. In a report issued on October 8, TD Cowen also maintained a Buy rating on the stock with a $99.00 price target.

Travere Therapeutics (TVTX)

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Travere Therapeutics on October 8 and set a price target of $20.00. The company’s shares closed last Wednesday at $17.59.

According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 12.4% and a 45.7% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Crinetics Pharmaceuticals, and Mereo Biopharma Group Plc.

Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $19.62, representing a 25.4% upside. In a report issued on September 27, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.

Read More on BHVN: